News

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...
Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...
Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...
Sixteen “safer” Ideal GASV emerged as buys for July. Top-ten tickers to buy were: CALM; FSK; MPLX; ET; YRD; ING; MO; VZ; NWBI ...
Key Points Warren Buffett's company Berkshire Hathaway has never paid a dividend.That hasn't stopped Buffett and his team ...
These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.
New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.
Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...
New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...
AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.